Table 3.
Antibodies | Case 1a* | Case 2 | Case 3 | Case 4 | Case 5 | Ratio |
---|---|---|---|---|---|---|
CK7 | + | + | + | + | + | 5/5 |
Cam5.2 | + | + | + | + | + | 5/5 |
Vimentin | + | + | + | + | + | 5/5 |
CD10 | + | + | + | + | + | 5/5 |
PAX2 | + | + | + | + | + | 5/5 |
VHL40 | + | + | − | − | + | 3/5 |
EMA | − | − | + | + | + | 3/5 |
CA125 | + | + | + | − | − | 3/5 |
WT-1 | + | + | − | − | + | 3/5 |
AR | − | − | + | − | + | 2/5 |
HBME-1 | + | + | − | − | − | 2/5 |
Calretinin | + | − | − | − | − | 1/5 |
RCC | − | − | + | − | − | 1/5 |
AR, Androgen receptor.
Similar results for both primary and implants.